Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Use of an epilepsy drug developed by GlaxoSmithKline and Valeant Pharmaceuticals should be restricted to patients for whom other anti-epileptic medicines have proved inadequate or not tolerated, EU regulators said on Friday. The European Medicines Agency said the move followed cases of abnormal coloring of the skin, nails, lips and eye tissues, including the retina, in some patients who took Trobalt.
Help employers find you! Check out all the jobs and post your resume.
